Revolutionizing Cancer Treatment: Key to Prolonging CAR T Cell Life Uncovered

FOXO1 is required for T cell memory and is linked to longer-lasting clinical outcomes in CAR T cell therapy.
CAR T cell therapy has transformed the way certain types of cancer are treated, and the longer those CAR T cells live in a patient’s body, the more effectively they respond to cancer.

Now, in a new study, researchers at Children’s Hospital of Philadelphia (CHOP) and Stanford Medicine have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers. The findings were recently published in the journal Nature.